IASO Bio's FUCASO demonstrates near‑complete response rates in heavily pretreated Chinese patients with relapsed/refractory plasma cell neoplasms
Executive summary: IASO Bio presented real‑world data from a Chinese study of 281 heavily pretreated patients with relapsed/refractory plasma cell neoplasms, showing FUCASO achieved a 95.9% objective response rate, 77.2% CR/sCR rate, and 94.1% MRD negativity. Such high response and deep remission rates suggest FUCASO could become a leading therapy for difficult‑to‑treat plasma cell neoplasms, potentially influencing treatment guidelines and attracting commercial interest.
Who is involved: IASO Bio (sponsor), Chinese clinical investigators, and the 2026 International Myeloma Society (IMS) meeting audience.
Likely next: Further follow‑up for overall survival, potential regulatory discussions with China’s NMPA, and presentation of longer‑term data at upcoming hematology conferences.
In a real‑world study of 281 heavily pretreated, predominantly high‑risk patients with relapsed/refractory plasma cell neoplasms, IASO Bio's FUCASO achieved a 95.9% objective response rate, a 77.2% complete‑or‑stringent complete response rate, and a 94.1% MRD negativity rate. Median progression‑free and overall survival were not yet reached at the time of reporting. The results position FUCASO among the most active CAR‑T therapies reported to date in this disease setting.
Timeline
- — 2026 IMS | IASO Bio Presented FUCASO China Real-World Data (PR Newswire)
- — 2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206 (PR Newswire)
- — 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T Cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression (PR Newswire)
Analysis — what this means
Sectors affected
- Relapsed/refractory plasma cell neoplasm therapy
- CAR-T cell therapy for hematologic malignancies
Historical parallels
- Updated FUMANBA-1 analysis of FUCASO (Sept 2025) showed durable CAR-T persistence associated with sustained MRD negativity
Key entities
Sources
- 2026 IMS | IASO Bio Presented FUCASO China Real-World Data — PR Newswire
- 2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206 — PR Newswire
- 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T Cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression — PR Newswire
Related cases
- IASO Bio's first-in-human data show its BCMA-targeted in vivo CAR-T therapy can achieve high response rates without chemotherapy, positioning it as a potential disruptor in the autologous CAR-T market
- IASO Bio's first-in-human Phase 1 data for the dual-targeted BCMA/GPRC5D CAR-T RD140 could redefine treatment for high-risk multiple myeloma, building on a pipeline that already includes FDA-cleared in vivo CAR-T assets
- LexisNexis and IMS launch edge-computing telematics to advance insurance intelligence beyond traditional UBI
- IASO Bio secures FDA clearance for first China-origin lentiviral in vivo CAR-T therapy
- Japan launches its first full-stack neutral-atom quantum computer, Shunkai, boosting national quantum capabilities